Skip to main content
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(2):207–216. doi: 10.1016/j.nurx.2006.01.014

Intervention for autistic spectrum disorders

Pauline A Filipek 1,2,4,, Robin Steinberg-Epstein 1,3, Teri M Book 1,2
PMCID: PMC3593433  PMID: 16554258

Summary

A comprehensive approach to the assessment of any child with autism must be matched specifically to each individual child and family. This premise holds for medical therapies and special education services as well as psychopharmacologic interventions. Behavioral, as opposed to pharmacologic, treatment is the hallmark of effective intervention for autism. Physicians involved in the care of children with autism need to become familiar with educational law and intervention recommendations. Goals should include improved functional verbal and nonverbal communication and social skills, increased engagement in developmentally appropriate activities, improved fine and gross motor skills, and the development of independent academic and organizations skills, as well as replacement of problem behaviors with developmentally appropriate behaviors. Medicating children with autism is difficult, but is often necessary for chronic behavioral difficulties. In the absence of clear and present guidelines, we have attempted to use evidence and clinical experience to suggest an algorithm based on symptom clusters. Although children with autism may be responsive to medications at lower doses and more susceptible to side effects than other children, medical intervention can produce a significant improvement in the quality of life for the child and family. Careful thought leading to correct identification of target behaviors can appropriately direct better alternatives for medication. Although these approaches are costly and time-consuming endeavors, the expenditure of such efforts is the only available pathway to improve the potential outcomes for individuals with autism as well as decrease the lifetime societal costs for each individual.

Key Words: Autism, treatment, intervention, special education, psychopharmacology, IDEA

References

  • 1.Diagnostic and statistical manual of mental disorders. Ed 4. Washington, DC: American Psychiatric Association; 1994. [Google Scholar]
  • 2.Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217–250. [PubMed] [Google Scholar]
  • 3.Waltz M, Shattock P, Carrey NJ. Autistic disorder in nineteenth-century London: three case reports Itard’s 1828 memoire on “Mutism caused by a lesion of the intellectual functions”: a historical analysis. Autism. 2004;8:7–20. doi: 10.1177/1362361304040635. [DOI] [PubMed] [Google Scholar]
  • 4.Carrey NJ. Itard’s 1828 memoire on “Mutism caused by a lesion of the intellectual functions”: a historical analysis. J Am Acad Child Adolesc Psychiatry. 1995;34:1655–1661. doi: 10.1097/00004583-199512000-00016. [DOI] [PubMed] [Google Scholar]
  • 5.Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1952. [Google Scholar]
  • 6.Diagnostic and statistical manual of mental disorders. Ed 2. Washington, DC: American Psychiatric Association; 1968. [Google Scholar]
  • 7.Diagnostic and statistical manual of mental disorders. Ed 3. Washington, DC: American Psychiatric Association; 1980. [Google Scholar]
  • 8.Diagnostic and statistical manual of mental disorders. Ed 3. Washington, DC: American Psychiatric Association; 1987. [Google Scholar]
  • 9.The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993. [Google Scholar]
  • 10.Lotter V. Epidemiology of autistic conditions in young children. I. Prevalence. Soc Psychiatry. 1966;1:124–137. doi: 10.1007/BF00584048. [DOI] [Google Scholar]
  • 11.Baird G, Charman T, Baron-Cohen S, Cox A, Swettenham J, Wheelwright S, et al. A screening for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694–702. doi: 10.1097/00004583-200006000-00007. [DOI] [PubMed] [Google Scholar]
  • 12.Prevalence of autism in Brick Township, New Jersey, 1998: community report. Atlanta, GA: Center for Disease Control and Prevention; 2000. [Google Scholar]
  • 13.Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093–3099. doi: 10.1001/jama.285.24.3093. [DOI] [PubMed] [Google Scholar]
  • 14.US Census Bureau. Fact Sheet: 2004 American community survey data profile highlights, 2005 Available at: http://factfinder.census.gov/servlet/ACSSAFFFacts?_event=&geo_id=01000US&_geo Context=01000US&_street=&_county=&_cityTown=&_state= &_zip=&_lang=en&_sse=on&ActiveGeoDiv=&_useEV=&pctxt =fph&pgsl=010. Accessed January 9, 2006.
  • 15.Bryson SE. Epidemiology of autism: overview and issues outstanding. In: Cohen DJ, Volkmar FR, editors. Handbook of autism and pervasive developmental disorders. Ed 2. New York: Wiley; 1997. pp. 41–46. [Google Scholar]
  • 16.Ehlers S, Gillberg C. The epidemiology of Asperger syndrome: a total population study. J Child Psychol Psychiatry. 1993;34:1327–1350. doi: 10.1111/j.1469-7610.1993.tb02094.x. [DOI] [PubMed] [Google Scholar]
  • 17.Wing L, Gould J. Severe impairments of social interaction and associated abnormalities in children: epidemiology and classification. J Autism Dev Disord. 1979;9:11–29. doi: 10.1007/BF01531288. [DOI] [PubMed] [Google Scholar]
  • 18.McLennan JD, Lord C, Schopler E. Sex differences in higher functioning people with autism. J Autism Dev Disord. 1993;23:217–227. doi: 10.1007/BF01046216. [DOI] [PubMed] [Google Scholar]
  • 19.Volkmar FR, Szatmari P, Sparrow SS. Sex differences in pervasive developmental disorders. J Autism Dev Disord. 1993;23:579–591. doi: 10.1007/BF01046103. [DOI] [PubMed] [Google Scholar]
  • 20.Allen DA. Autistic spectrum disorders: clinical presentation in preschool children. J Child Neurol. 1988;3:S48–S56. doi: 10.1177/088307388800300110. [DOI] [PubMed] [Google Scholar]
  • 21.Wing L. The continuum of autistic disorders. In: Schopler E, Mesibov GM, editors. Diagnosis and assessment in autism. New York: Plenum; 1988. pp. 91–110. [Google Scholar]
  • 22.Wing L. The autistic spectrum. Lancet. 1997;350:1761–1766. doi: 10.1016/S0140-6736(97)09218-0. [DOI] [PubMed] [Google Scholar]
  • 23.Porter B, Goldstein E, Galil A, Carel C. Diagnosing the ‘strange’ child. Child Care Health Dev. 1992;18:57–63. doi: 10.1111/j.1365-2214.1992.tb00340.x. [DOI] [PubMed] [Google Scholar]
  • 24.Deb S, Prasad KB. The prevalence of autistic disorder among children with a learning disability. Br J Psychiatry. 1994;165:395–399. doi: 10.1192/bjp.165.3.395. [DOI] [PubMed] [Google Scholar]
  • 25.Bhaumik S, Branford D, McGrother C, Thorp C. Autistic traits in adults with learning disabilities. Br J Psychiatry. 1997;170:502–506. doi: 10.1192/bjp.170.6.502. [DOI] [PubMed] [Google Scholar]
  • 26.Jensen VK, Larrieu JA, Mack KK. Differential diagnosis between Attention-Deficit/ Hyperactivity Disorder and Pervasive Developmental Disorder-Not Otherwise Specified. Clin Pediatr. 1997;36:555–561. doi: 10.1177/000992289703601001. [DOI] [PubMed] [Google Scholar]
  • 27.Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, et al. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord. 1999;29:437–482. doi: 10.1023/A:1021943802493. [DOI] [PubMed] [Google Scholar]
  • 28.Hirtz D, Wagner A, Filipek PA. The autistic spectrum disorders. In: Swaiman KF, Ashwal S, Ferreiro DM, editors. Pediatric neurology: principles and practice. Philadelphia: WB Saunders-Mosby; 2006. [Google Scholar]
  • 29.Volkmar FR, Paul R, Klin A, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders. Ed 3. New York: Wiley; 2005. [Google Scholar]
  • 30.Lord C, Bristol-Power M, Cafiero JM, Filipek PA, Gallagher JJ, Harris SL, et al. Educating children with autism. In: Lord C, McGee JP, et al., editors. Report of the Committee on Educational Interventions for Autistic Children. Washington, DC: National Academy of Science, National Academies Press; 2001. [Google Scholar]
  • 31.JADD Special Issue: NAS Workshop Papers.J Autism Dev Disord 32:349-508, 2002.
  • 32.Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462–1470. doi: 10.1056/NEJMhpr021646. [DOI] [PubMed] [Google Scholar]
  • 33.Blumer JL. Off-label uses of drugs in children. Pediatrics. 1999;104:598–602. [PubMed] [Google Scholar]
  • 34.Filipek PA. Medical aspects of autism. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders. New York: Wiley; 2005. pp. 534–578. [Google Scholar]
  • 35.McDougle CJ, Posey DJ. Genetics of childhood disorders: XLIV Autism. Part 3: Psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry. 2002;41:1380–1383. doi: 10.1097/00004583-200211000-00021. [DOI] [PubMed] [Google Scholar]
  • 36.Walkup JT, Labellarte MJ, Riddle MA, Pine DS, Greenhill L, Klein R, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344:1279–1285. doi: 10.1056/NEJM200104263441703. [DOI] [PubMed] [Google Scholar]
  • 37.Lewis MH, Lazoritz M. Psychopharmacology of autism spectrum disorders.Psychiatric Times 22, 2005.
  • 38.Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol. 2005;15:116–126. doi: 10.1089/cap.2005.15.116. [DOI] [PubMed] [Google Scholar]
  • 39.Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999;38:923–931. doi: 10.1097/00004583-199907000-00024. [DOI] [PubMed] [Google Scholar]
  • 40.Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–589. doi: 10.1038/sj.npp.1300627. [DOI] [PubMed] [Google Scholar]
  • 41.Buitelaar JK, Willemsen-Swinkels SH. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatrics Drugs. 2000;2:67–81. doi: 10.2165/00148581-200002010-00006. [DOI] [PubMed] [Google Scholar]
  • 42.Quintana H, Birmaher B, Stedge D, Lennon S, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283–294. doi: 10.1007/BF02179289. [DOI] [PubMed] [Google Scholar]
  • 43.Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.Arch Gen Psychiatry 62:1266-1274, 2005. [DOI] [PubMed]
  • 44.McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry. 2003;64:16–25. [PubMed] [Google Scholar]
  • 45.Anderson LT, Campbell M, Actams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19:227–239. doi: 10.1007/BF02211843. [DOI] [PubMed] [Google Scholar]
  • 46.McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321. doi: 10.1056/NEJMoa013171. [DOI] [PubMed] [Google Scholar]
  • 47.Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–e641. doi: 10.1542/peds.2003-0264-F. [DOI] [PubMed] [Google Scholar]
  • 48.Di Martino A, Tuchman RF. Antiepileptic drugs:affective use in autism spectrum disorders. Pediatric Neurol. 2001;25:199–207. doi: 10.1016/S0887-8994(01)00276-4. [DOI] [PubMed] [Google Scholar]
  • 49.Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:682–692. doi: 10.1089/cap.2005.15.682. [DOI] [PubMed] [Google Scholar]
  • 50.Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.J Child Adolesc Psychopharmacology (in press). [DOI] [PubMed]
  • 51.Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J. Volumetric MRI analysis comparing attention-deficit hyperactivity disorder and normal controls. Neurology. 1997;48:589–601. doi: 10.1212/WNL.48.3.589. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES